Pregabalin Add-on Treatment: A Randomized, Double-blind, Placebo-controlled, Dose-Response Study in Adults with Partial Seizures

Epilepsia

Volumn 45, Issue 1, 2004, Pages 20-27

  Arroyo, Santiago ^a   Anhut, Henning ^b   Kugler, Alan R ^b   Lee, Caroline M ^b   Knapp, Lloyd E ^b   Garofalo, Elizabeth A ^b   Messmer, Silke ^b  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

Add on; Adjunctive; AED; Anticonvulsant; Epilepsy; Partial seizures; Pregabalin; Randomized

Indexed keywords

3 ISOBUTYL GABA; 3-ISOBUTYL GABA; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; DRUG DERIVATIVE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTICONVULSANT THERAPY; ARTICLE; ASTHENIA; ATAXIA; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; VISUAL IMPAIRMENT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED;

EID: 0347985301     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.31203.x     Document Type: Article

References (27)

1. Selak I. Pregabalin (Pfizer). Curr Opin Invest Drugs 2001;2:828-34.
2. Ben-Menachem E, Kugler AR. Pregabalin. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:901-5.
3. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
4. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.
5. French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-7.
6. Beydoun AA, Uthman BM, Ramsay RE, et al. Pregabalin addon trial: double-blind, multicenter study in patients with partial epilepsy. Epilepsia 2000;41(suppl 7):253-4.
7. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
8. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:226-36.
9. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10.
10. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93.
11. 3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93:191-6.
12. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:13341.
13. Errante LD, Petroff OAC. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003;12:300-6.
14. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:141.
15. Welty D, Wang Y, Busch JA et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock. Epilepsia 1997;38(suppl 8): 35.
16. Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19:149-77.
17. Taylor CP, Vartanian MG. Profile of anticonvulsant activity of pregabalin in animal models. Epilepsia 1997;38(suppl 8):35.
18. Williamson J, Lothman CTE, Bertram E. Comparison of S-(+)-3 isobutyl GABA (pregabalin) and gabapentin against kindled hippocampal seizures. Epilepsia 1997;38(suppl 8):29.
19. Pfizer Inc. Data on file. Ann Arbor, Michigan, U.S.A.
20. Kugler AR, Garofalo EA. Pregabalin adjunctive therapy in patients with partial seizures: presented at the Southern Clinical Neurological Meeting. Costa Rica, 2001.
21. Bockbrader HN, Burger PJ, Corrigan BW, et al. Population pharmacokinetic (PK) analyses of pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia 2001;42(suppl 7): 84.
22. Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981;22:489-501.
23. Department of Health and Human Services. Coding symbols for a thesaurus of adverse event reaction terms (COSTART). 4th ed. Rockville, MD: Department of Health and Human Services, US Food and Drug Administration (FDA), 1996.
24. Rubërg S. Contrasts for identifying the minimum effective dose. J Am Stat Assoc 1989;84:816-22.
25. Cramer JA, Mattson RH, Scheyer RD, et al. Review of new antiepileptic drugs (AEDs). Epilepsia 1998;39:233-4.
26. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40:590-600.
27. Miller R, Frame B, Corrigan B, et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Thera 2003;73:491-505.